Elicio Therapeutics (ELTX) Current Assets (2020 - 2026)

Elicio Therapeutics (ELTX) has reported Current Assets for 7 consecutive years, with $25.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Assets rose 12.78% year-over-year to $25.5 million; the trailing twelve-month figure through Jun 2026 stood at $25.5 million (up 12.78% YoY), and the FY2025 full-year result was $19.3 million, down 6.68% from the prior year.
• Current Assets rose to $25.5 million in Q2 2026 per ELTX's latest filing, from $16.2 million in the prior quarter.
• Across five years, Current Assets topped out at $76.2 million in Q1 2022 and bottomed at $6.7 million in Q2 2024.
• Historically, Current Assets has averaged $28.4 million across 5 years, with a median of $21.2 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Current Assets tumbled 88.25% in 2022, then jumped 237.84% in 2025.
• Over 5 years, Current Assets stood at $10.7 million in 2022, then jumped by 52.54% to $16.3 million in 2023, then gained by 26.58% to $20.7 million in 2024, then declined by 6.68% to $19.3 million in 2025, then surged by 31.97% to $25.5 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $25.5 million, $16.2 million, and $19.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.